Week in Review: Hutchison Chi-Med Forms Drug Development JV with Nestlé
Hutchison Chi-Med and Nestlé formed a JV based on Chi-Med’s expertise in TCM, including Hutchison’s drug candidate for ulcerative colitis and Crohn’s disease; Crown Bioscience will join with Beijing Purunao Biotech to develop small molecule drugs aimed at oncology targets; Fosun Pharma and the Shanghai Institute of Materia Medica will jointly develop an innovative oncology drug; a 24% stake in China Pharmaceutical R&D Center Co. is up for sale at a price of $2.5 million; ChinaBio® recently completed a survey of 70 participants in the China healthcare sector, finding that they have grown more optimistic over the past year; AstraZeneca was given SFDA approval for Brilinta, a drug that fights blood clots, Qiagen won SFDA approval for its careHPV Test, an HPV test for remote areas; and TTY Biopharm, a Taiwanese drugmaker, opened its new $100 million drug manufacturing facility in Suzhou. More details…. Stock Symbols: (AIM: HCM) (SHA: 600196; HK: 2196) (NYSE: AZN) (NSDQ: QGEN) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here